Sunday, June 14, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Dow Jones

IBM Delivers Earnings Beat but Consulting Stagnation Triggers Sharp Selloff

Kennethcix by Kennethcix
April 26, 2026
in Dow Jones, Earnings, Tech & Software
0
IBM Stock
0
SHARES
25
VIEWS
Share on FacebookShare on Twitter

Investors who looked past the headline numbers at IBM’s first-quarter results found a story of two very different businesses. The software division surged, mainframe revenue exploded, and earnings per share comfortably cleared analyst estimates. Yet the stock tumbled more than 9% in the aftermath, as the market zeroed in on a persistent weak spot: consulting.

For the three months ended March 31, IBM reported adjusted earnings of $1.91 per share, beating the consensus forecast of $1.82 by roughly 5.5%. Revenue came in at $15.92 billion, up 9.5% year-over-year and slightly ahead of expectations. Adjusted EBITDA surpassed estimates by 13%. On the surface, it was a clean beat.

Software revenue climbed 11% to $7.05 billion, while infrastructure — powered by a 51% surge in Z-mainframe sales — delivered a strong contribution. Management reaffirmed its full-year outlook for constant-currency revenue growth above 5% and an additional $1 billion in free cash flow compared with 2025.

But the consulting business, which IBM is counting on to help transform its customer base into a higher-margin software operation, grew just 1% on a currency-adjusted basis. That figure landed well below the double-digit expansion needed to justify the premium valuation investors have assigned to the stock.

“That’s the price of wanting to be valued as a software company — investors don’t like results that merely meet consensus,” said Melius Research analyst Ben Reitzes, capturing the market’s disappointment. The contrast is stark: software carries gross margins of 82%, while consulting margins hover around 28%. As long as the consulting unit stagnates, the overall margin profile remains capped.

The selloff spilled over to rivals. Shares of Accenture also retreated as the market reassessed the risk of a broader slowdown in IT consulting. At roughly 19 times forward earnings, IBM trades well above its five-year average of 14 times — a premium that looked justified when both software and consulting were growing at double-digit rates. With software at 11% and consulting at 1%, that foundation has cracked.

Should investors sell immediately? Or is it worth buying IBM?

Chief Financial Officer Jim Kavanaugh struck a cautious tone on the analyst call, describing IBM as a “prudent operator” and noting that raising guidance in the first quarter would be historically unusual. The company also flagged headwinds from the pending acquisition of Confluent, which is expected to create dilution. Wedbush maintained its outperform rating but trimmed its price target from $340 to $320, citing those factors along with temporary weakness in consulting.

The stock closed at €193.88 in Frankfurt, roughly 29% below its 52-week high of €271.80 and more than 22% lower than where it started the year. It now sits well below its 200-day moving average.

IBM announced two strategic partnerships alongside its earnings. A collaboration with Google Cloud aims to accelerate enterprise AI adoption and modernize hybrid cloud infrastructure, combining Google’s developer-friendly approach with IBM’s hybrid cloud and data management expertise. Separately, IBM is integrating its agentic AI platform watsonx Orchestrate into Adobe’s customer experience automation tools, helping companies detect and respond to customer intent more quickly.

For income-focused investors, the dividend calendar offers a concrete date. The ex-dividend date is May 8, with a payout of $1.69 per share scheduled for June 10. It marks the 31st consecutive year that IBM has increased its quarterly dividend.

Whether that is enough to draw buyers back remains an open question. The stock is trading just above its 52-week low, and the path to recovery runs through consulting. Until that business shows signs of a rebound, the software valuation will be hard to defend.

Ad

IBM Stock: Buy or Sell?! New IBM Analysis from June 14 delivers the answer:

The latest IBM figures speak for themselves: Urgent action needed for IBM investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 14.

IBM: Buy or sell? Read more here...

Tags: IBM
Kennethcix

Kennethcix

Related Posts

Uranium Energy Stock
Analysis

Uranium Energy’s $52 Million Quarter: No Revenue, a New Texas Mine, and a $794 Million Cushion

June 14, 2026
Amazon Stock
Analysis

Amazon’s Freight Gambit and Regulatory Headwinds Eclipse Prime Day Hype

June 14, 2026
Micron Stock
AI & Quantum Computing

Micron’s 215% Rally Meets Its First Real Test: Can the Stock Justify the Hype Before June 24?

June 14, 2026
Next Post
Apple Stock

Apple Faces a Rare Convergence of Tailwinds and Turbulence Ahead of Earnings

Bloom Energy Stock

Bloom Energy's April 28 Earnings: Can a $20 Billion Backlog Justify a 1,300% Surge?

Broadcom Stock

Broadcom’s AI Chip Empire Tightens as Golden Cross Signals More Upside

Recommended

Novo Nordisk Stock

Novo Nordisk Bets on Oral Wegovy to Expand Weight-Loss Market Reach

5 months ago
Blackrock Stock

BlackRock’s Global Strategy: Dividend Payouts and Market Expansion

9 months ago
D-Wave Quantum Stock

D-Wave Quantum: A Story of High Ambition Amidst Financial Crosscurrents

3 months ago
Ooma Stock

Ooma Stock: A Clash Between Analyst Optimism and Insider Selling

9 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Netflix Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics XRP
No Result
View All Result

Highlights

Ocugen Faces a Moment of Truth as Clinical Catalysts Collide With a 55% Plunge

Amazon’s Freight Gambit and Regulatory Headwinds Eclipse Prime Day Hype

OHB’s Record Backlog and a Shifting Shareholder Base Set the Stage for a Defining Summer

Germany’s Communities Feel the Squeeze as Labour Shortage Forecast Worsens by 1.3 Million

European Lithium Faces a Trio of Hurdles as Lithium Markets Show Signs of Turning

OHB’s Free Float Squeeze Nears a Release as KKR Exit and Rocket Flight Converge

Trending

Novo Nordisk Stock
Analysis

Novo Nordisk Sharpens Its Pipeline Edge as Longevity Pivot Takes Shape

by Rodolfo Hanigan
June 14, 2026
0

The Danish pharmaceutical heavyweight arrived at the American Diabetes Association congress in New Orleans armed with a...

BMW Stock

BMW Executive Puts Money on Recovery After Stock Plunge, as Electric M-Concept Unveiled at Le Mans

June 14, 2026
Uranium Energy Stock

Uranium Energy’s $52 Million Quarter: No Revenue, a New Texas Mine, and a $794 Million Cushion

June 14, 2026
Ocugen Stock

Ocugen Faces a Moment of Truth as Clinical Catalysts Collide With a 55% Plunge

June 14, 2026
Amazon Stock

Amazon’s Freight Gambit and Regulatory Headwinds Eclipse Prime Day Hype

June 14, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Novo Nordisk Sharpens Its Pipeline Edge as Longevity Pivot Takes Shape
  • BMW Executive Puts Money on Recovery After Stock Plunge, as Electric M-Concept Unveiled at Le Mans
  • Uranium Energy’s $52 Million Quarter: No Revenue, a New Texas Mine, and a $794 Million Cushion

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com